Skip to content

Stock to watch: Cardlytics (CDLX) raises Q1 revenue guidance as buying pressure mounts

Stock to watch: Cardlytics (CDLX) raises Q1 revenue guidance as buying pressure mounts
Ana Zirojevic

The stock of finance-focused digital advertising platform Cardlytics (NASDAQ: CDLX), which had been on the downside for most of the past month, has suddenly experienced a significant uptick upon the company announcing its updated guidance for the first quarter of 2023.

Indeed, the updated guidance on Cardlytics’ financial results for the quarter ending March 31, 2023, shows higher billings, revenue, and adjusted contribution, than on previously reported guidance, according to the company’s press release on April 4.

Cardlytics previously reported vs. updated guidance for Q1 2023. Source: GlobeNewswire

Commenting on the update, Cardlytics CEO Karim Temsamani said:

“Our improved topline guidance is driven by better-than-expected growth in the U.S. business and the product optimizations discussed on our last earnings call. (…) We are confidently navigating 2023 and look forward to sharing more positive updates over the coming months.”

Cardlytics stock responds

Shortly after the announcement, the Cardlytics stock witnessed “an abrupt price boost on high relative volume (11 RVOL),” as earlier observed on the Twitter page of the stock market analytics and monitoring platform TT Day Trading Alerts. 

Cardlytics price and volume on April 4. Source: TT Day Trading Alerts

As things stand, CDLX is currently changing hands at $4.64, up more than 30% in the last 24 hours and nearly 64% in the past five days, as per the latest Google Finance real-time market data obtained by Finbold on April 4.

Cardlytics five-day price chart. Source: Google Finance

With the newest results, the CDLX stock has broken through the previous resistance level at $4.24, set by the stock trader and finance analyst Tiger Line Trading, and is now on the way towards the New High of Day (NHOD), as the expert projected earlier during the day.

Cardlytics price candles on April 4. Source: Tiger Line Trading

Interestingly, investment analyst Austin Swanson stated earlier in March that CDLX could increase its price in April based on factors such as possible upcoming announcements on better earnings results, as well as the updated liquidity analysis, among other things.

Buy stocks now with Interactive Brokers – the most advanced investment platform


Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account? Sign In

Services

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.